Overview

Neuralink is a commercial BCI company, pursuing direct brain implants through minimally invasive robotic insertion. Founded in 2016 with backing from CEO Elon Musk, the company has raised over $1 billion in funding, including a $650 million Series E round in June 2025, reaching a reported valuation of approximately $9 billion.

Technical Approach

The N1 implant contains 1,024 electrodes distributed across 64 flexible polymer threads, each thinner than a human hair. Neuralink developed proprietary robotic surgical equipment to insert the electrode threads into the motor cortex, reducing surgical complexity compared to traditional open-brain procedures.

Clinical Progress

Neuralink’s PRIME study (Precise Robotically Implanted Brain-Computer Interface) and its Canadian, UK and UAE arms had implanted 26 participants by May 2026. The company received FDA Breakthrough Device Designation, accelerating its regulatory pathway. Participants have demonstrated control of computer cursors and robotic arms through neural signals. The company is advancing toward broader clinical applications in spinal cord injury and motor neuron disease. A separate VOICE trial (NCT07224256) is testing speech restoration, and in October 2026 Neuralink reported pretraining participant-specific decoders on more than 50,000 hours of everyday brain recordings, cutting some users’ calibration from about 10 minutes a day to 10 minutes a week.

Manufacturing and operations

Neuralink’s primary research and engineering headquarters remain in Fremont, California, but the company is constructing and operating a large-scale three-story manufacturing, machining, and cleanroom facility in Del Valle, Austin, Texas, located approximately 10 miles east of the Tesla Gigafactory. The Austin expansion is positioned as the company’s future manufacturing scale and supply chain backbone, supporting the projected throughput required for broader clinical and eventual commercial deployment of the N1 implant and associated robotic surgical equipment.

Competitive Position

Neuralink’s combination of high electrode count, automated implantation robotics, and aggressive funding timeline positions it as the leading contender in the race toward high-bandwidth brain-computer interfaces for paralyzed patients.